Literature DB >> 22505396

Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure.

Matthias Dupont1, Kevin Shrestha, Dhssraj Singh, Adiveh Awad, Cynthia Kovach, Mario Scarcipino, Anjli P Maroo, W H Wilson Tang.   

Abstract

AIMS: Acute kidney injury (AKI) is a strong predictor of adverse events with an incompletely understood pathophysiology. Neutrophil gelatinase-associated lipocalin (NGAL) is proposed as an early marker of renal tubular injury. Our aim is to determine whether AKI during treatment of acute decompensated heart failure (ADHF) is accompanied by renal tubular injury. METHODS AND
RESULTS: Urinary NGAL (uNGAL) and urinary creatinine (uCreat) levels were measured in 141 consecutive patients hospitalized for ADHF and followed for 180 days for death or re-hospitalization. AKI was defined as a rise in serum creatinine ≥0.3 mg/dl in a 48 h period. Median uNGAL/uCreat levels on Day 1 (baseline) were similar between patients who did and did not develop AKI [22.8 (12.5-106.8) μg/g vs. 20.6 (12.4-52.0) μg/g, P = 0.55]. On Day 2 and beyond, the difference between the AKI and no AKI cohorts increased, but was only significant on Day 3 [36.2 (21.7-131.8) μg/g vs. 29.4 (11.4-54.6) μg/g, P = 0.02]. The area under the receiver operating characteristic curve for Day 2 uNGAL/uCreat (≥ or <32 µg/g) to predict AKI was 0.61. There was no difference in diuretic response between 'uNGAL/uCreat + ' (≥ 27 µg/g) and 'uNGAL/uCreat-' (<27 µg/g) patients. However 'uNGAL/uCreat + ' patients had more adverse events after 180 days (66% vs. 52%, P = 0.02).
CONCLUSIONS: In patients with ADHF who develop AKI following diuretic therapy, a minor rise in uNGAL precedes AKI. However, the degree of renal tubular insult was much lower than that observed in other forms of AKI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505396      PMCID: PMC3359861          DOI: 10.1093/eurjhf/hfs039

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  34 in total

1.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Authors:  Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

2.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.

Authors:  Jaya Mishra; Catherine Dent; Ridwan Tarabishi; Mark M Mitsnefes; Qing Ma; Caitlin Kelly; Stacey M Ruff; Kamyar Zahedi; Mingyuan Shao; Judy Bean; Kiyoshi Mori; Jonathan Barasch; Prasad Devarajan
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

Review 3.  Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia.

Authors:  Kai M Schmidt-Ott; Kiyoshi Mori; Avtandil Kalandadze; Jau-Yi Li; Neal Paragas; Thomas Nicholas; Prasad Devarajan; Jonathan Barasch
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-07       Impact factor: 2.894

4.  Superoxide enhances Na-K-2Cl cotransporter activity in the thick ascending limb.

Authors:  Ramiro Juncos; Jeffrey L Garvin
Journal:  Am J Physiol Renal Physiol       Date:  2005-05

5.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).

Authors:  G S Francis; C Benedict; D E Johnstone; P C Kirlin; J Nicklas; C S Liang; S H Kubo; E Rudin-Toretsky; S Yusuf
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

6.  Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin.

Authors:  Jaya Mishra; Kiyoshi Mori; Qing Ma; Caitlin Kelly; Jun Yang; Mark Mitsnefes; Jonathan Barasch; Prasad Devarajan
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

7.  Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis.

Authors:  G S Francis; R M Siegel; S R Goldsmith; M T Olivari; T B Levine; J N Cohn
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

8.  Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function.

Authors:  S Ljungman; J H Laragh; R J Cody
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 9.  The role of reactive oxygen species in the regulation of tubular function.

Authors:  J L Garvin; P A Ortiz
Journal:  Acta Physiol Scand       Date:  2003-11

Review 10.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097

View more
  30 in total

Review 1.  Synthesizing Markers of Kidney Injury in Acute Decompensated Heart Failure: Should We Even Keep Looking?

Authors:  Alexander S Manguba; Xavier Vela Parada; Steven G Coca; Anuradha Lala
Journal:  Curr Heart Fail Rep       Date:  2019-12

2.  Urinary Angiotensinogen Level Predicts AKI in Acute Decompensated Heart Failure: A Prospective, Two-Stage Study.

Authors:  Xiaobing Yang; Chunbo Chen; Jianwei Tian; Yan Zha; Yuqin Xiong; Zhaolin Sun; Pingyan Chen; Jun Li; Tiecheng Yang; Changsheng Ma; Huafeng Liu; Xiaobin Wang; Fan Fan Hou
Journal:  J Am Soc Nephrol       Date:  2015-02-26       Impact factor: 10.121

3.  Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure.

Authors:  Frederik H Verbrugge; Matthias Dupont; Zhili Shao; Kevin Shrestha; Dhssraj Singh; Michael Finucan; Wilfried Mullens; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09       Impact factor: 5.712

Review 4.  The kidney in heart failure: an update.

Authors:  Kevin Damman; Jeffrey M Testani
Journal:  Eur Heart J       Date:  2015-04-02       Impact factor: 29.983

Review 5.  Management of the cardiorenal syndrome in decompensated heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Cardiorenal Med       Date:  2014-12       Impact factor: 2.041

Review 6.  Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins.

Authors:  Suree Lekawanvijit; Henry Krum
Journal:  J Physiol       Date:  2014-06-06       Impact factor: 5.182

Review 7.  Novel renal biomarkers to assess cardiorenal syndrome.

Authors:  Meredith A Brisco; Jeffrey M Testani
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 8.  The acute cardiorenal syndrome: burden and mechanisms of disease.

Authors:  Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 9.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

Review 10.  Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure.

Authors:  Frederik Hendrik Verbrugge
Journal:  Curr Heart Fail Rep       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.